Assessing Feasibility and Utility of Enhancing Medication Therapy Management With Pharmacist-Delivered Pharmacogenetic Testing
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Pharmacogenetics
- Sponsor
- Duke University
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Number of recommended drug selection/dosing adjustments
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
This study aims to investigate the benefit and feasibility of providing pharmacogenetic (PGx) testing as part of a standard medication therapy management (MTM) session for patients taking multiple medications, a high-risk population for adverse drug reactions and non-response. Research participants will attend two MTM sessions and undergo PGx testing to inform the MTM plan. Participants will also complete 2 surveys pre and post-MTM/PGx testing. Data analysis will assess the impact of MTM/PGx testing on recommendations for drug dosing, clinical outcomes, patient satisfaction, and feasibility of service delivery. Safety issues are minimal with the primary risks being associated with loss of confidentiality, typical discomfort associated with acquiring blood samples, and genetic discrimination.
Investigators
Eligibility Criteria
Inclusion Criteria
- •currently prescribed 3 medications, one of which must be simvastatin or clopidogrel
- •18 years of age or older
- •English speaking
- •patients of Mahesh Patel or William Kraus at Duke Southpoint Clinic
Exclusion Criteria
- •if patient has ever had MTM or PGx
Outcomes
Primary Outcomes
Number of recommended drug selection/dosing adjustments
Time Frame: approximately 9 months
Drug selection/doing changes will be compared between study population and chart-review controls
Patient satisfaction with MTM and PGx
Time Frame: 3 months after completion of MTM2
This will be assessed by a quantitative survey
Change in clinical biomarkers associated with drug therapy
Time Frame: baseline and 2 months
Changes in biomarkers before and after MTM/PGx will be measured. Biomarkers of study group will be compared to chart-review control
Secondary Outcomes
- Physician time to perform MTM and PGx(end of study, approx. 9 months)